Holen Sie sich die Stockscreener-App
43.65
1.32%
0.57
Vorhandelsmarkt:
43.88
0.23
+0.53%
Schlusskurs vom Vortag:
$43.08
Offen:
$43.56
24-Stunden-Volumen:
1.25M
Relative Volume:
1.14
Marktkapitalisierung:
$9.71B
Einnahmen:
$1.94B
Nettoeinkommen (Verlust:
$72.70M
KGV:
30.10
EPS:
1.45
Netto-Cashflow:
$405.21M
1W Leistung:
+4.43%
1M Leistung:
+0.18%
6M Leistung:
+1.56%
1J Leistung:
+7.98%
1-Tages-Spanne:
$43.45
$43.85
1-Wochen-Bereich:
$41.58
$43.85
52-Wochen-Spanne:
$38.68
$47.44
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel - Yahoo Finance
Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics - GlobeNewswire
Qiagen Receives FDA Clearance Of Qiastat-Dx Meningitis/Encephalitis Panel To Support Emergency Diagnostics - XM
Forsta AP Fonden Sells 18,586 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen (QGEN) Set to Announce Earnings on Wednesday - MarketBeat
Raymond James & Associates Trims Position in Qiagen (NYSE:QGEN) - MarketBeat
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire Inc.
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment - GlobeNewswire
Qiagen Receives FDA Clearance For Qiastat-Dx Mini Panel - XM
Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note - MSN
Insiders At Qiagen Sold US$7.0m In Stock, Alluding To Potential Weakness - Simply Wall St
Qiagen (NYSE:QGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Verogen Hit With Genetic-Privacy Suit Over Acquisition by Qiagen - Bloomberg Law
HSBC Downgrades Qiagen N.V. (QGEN) - MSN
Cancer Biomarkers Industry Analysis and Market Opportunities, Forecast to 2029A Forecasted $42 Billion Landscape, Dominated by Roche, Thermo Fisher Scientific, QIAGEN, Illumina, and Bio-Rad Labs - Yahoo Finance
Vontobel Holding Ltd. Sells 29,019 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen (NYSE:QGEN) Upgraded at Hsbc Global Res - MarketBeat
Qiagen N.V. (NYSE:QGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Qiagen (NYSE:QGEN) Rating Lowered to Hold at HSBC - MarketBeat
HSBC cautious on Qiagen stock, highlights pricing and revenue risks - Investing.com
HSBC cautious on Qiagen stock, highlights pricing and revenue risks By Investing.com - Investing.com Canada
HSBC Downgrades Qiagen NV (QGEN) to Hold - StreetInsider.com
QIAGEN NV : DZ Bank reiterates its Buy rating - Marketscreener.com
CE Mark Granted To Qiagen's QIAstat-Dx Syndromic Testing Instruments, Assays - MPO-mag
Mycoplasma Plate Antigen Market 2024-2031- Charles River, Prospec-Tany Technogene Ltd, Abnova Corporation, Qiagen N.V., – IndiaPolitics.com - IndiaPolitics.com
Cubist Systematic Strategies LLC Decreases Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Is in Huge Demand:Qiagen NV, GE Healthca – IndiaPolitics.com - IndiaPolitics.com
Exchange Traded Concepts LLC Sells 62,505 Shares of Qiagen (NYSE:QGEN) - MarketBeat
QIAGEN's TB Testing Business Gets New Exposure at Global Summit - Yahoo Finance
Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S - Simply Wall St
QIAGEN expands automated liquid biopsy portfolio to enhance - GlobeNewswire
QIAGEN Expands Automated Liquid Biopsy Portfolio To Enhance Oncology, Prenatal Care And Organ Transplant Applications - XM
QIAGEN Expands Automated Liquid Biopsy Portfolio to Enhance Oncology, Prenatal Care and Organ Transplant Applications - Marketscreener.com
QIAGEN N.V. to release results for Q3 2024 and hold webcast - The Manila Times
QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications - StockTitan
Handelsbanken Fonder AB Purchases 19,900 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen N : Digital Insights Expands Biopharma Collaboration with Neo4j to advance Biomedical Data Analysis - Marketscreener.com
Reasons to Retain QIAGEN Stock in Your Portfolio for Now - MSN
Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer - The Manila Times
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology - SelectScience
QGENQIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology - br.ADVFN.com
Oxidative Stress Analysis Market Dynamics Analysis – Abcam, Enzo Biochem, Merck, Qiagen NV - Cauverynews
Qiagen launches QIAcuityDx digital PCR system for clinical testing in oncology - BSA bureau
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.73%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):